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Abstract Celiac disease (CD) is an autoimmune disorder of the small intestine triggered by environmental factors in
genetically predisposed individuals. A strong association between type 1 diabetes (T1DM) and CD has been reported. We
have previously shown that rotavirus infection may be involved in the pathogenesis of CD through a mechanism of
molecular mimicry. Indeed, we identified a subset of anti-transglutaminase IgA antibodies that recognize the rotavirus viral
protein VP7. In this study, we aimed at evaluating whether such antibodies may predict the onset of CD in children affected
by T1DM. Moreover, to further analyze the link between rotavirus infection and pathogenesis of CD, we analyzed the
effect of anti-rotavirus VP7 antibodies on T84 intestinal epithelial cells using the gene-array technique, complemented by
the analysis of molecules secreted in the supernatant of stimulated cells. We found that anti-rotavirus VP7 antibodies are
present in the vast majority (81 %) of T1DM-CD tested sera, but are detectable also in a fraction (27 %) of T1DM children
without CD. Moreover, we found that anti-rotavirus VP7 antibodies are present before the CD onset, preceding the
detection of anti-tTG and anti-endomysium antibodies. The gene-array analysis showed that purified anti-rotavirus VP7
antibodies modulate genes that are involved in apoptosis, inflammation, and alteration of the epithelial barrier integrity in
intestinal epithelial cells, all typical features of CD. Taken together, these new data further support the involvement of
rotavirus infection in the pathogenesis of CD and suggest a predictive role of anti-rotavirus VP7 antibodies.
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Introduction
Celiac disease (CD) is an inflammatory disorder of the
small intestine characterized by a permanent intolerance to
gluten-derived peptides that may affect as many as 1–3 %
of the European and North American populations [1].
CD is a multifactorial disorder and both genetic and
environmental factors are required for the disease phenotype
to develop [2]. Among environmental factors, infections
were thought to play a role in the etiopathogenesis of the
disease; however, a direct link was still missing; in our
attempt to clarify some aspects of the disease pathogenesis,
we used a random peptide library approach that we had
previously successfully applied to the study of other auto-
immune diseases [3–6].
By means of this strategy, we were able to identify a
peptide (called celiac peptide) recognized by serum
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immunoglobulins of patients with active disease [7]; this
peptide shares homology with the rotavirus major neutral-
izing protein VP7 and with the self-antigen tissue transglu-
taminase (tTG) (Fig. 1). Surprisingly, antibodies directed
against the celiac peptide, purified from the sera of patients
with active disease, recognized rotavirus major neutralizing
protein VP7 and the self-antigen tTG.We also demonstrated
that in active CD, a subset of anti-transglutaminase IgA
antibodies recognize the viral protein VP7, suggesting a
possible involvement of rotavirus infection in the patho-
genesis of the disease and thus identifying a potential link
between rotavirus infection and the onset of CD: these
antibodies seem to be a hallmark of active disease and have
never been detected in healthy controls. Interestingly, it has
been observed that rotavirus can induce the same mucosal
villous atrophy that is induced by gluten in CD in small
intestine [8].
The link between rotavirus infection and the risk to
develop CD was supported by an epidemiological study
conducted in a large population of children carrying the
risk allele for CD [9]. The association between Type 1
diabetes (T1DM) and CD is frequent, and the two diseases
share a common genetic background that may be explained
by the combined presence of HLA-DQ transdimer termed
HLA-DQ8 trans [10].
It has been shown that the prevalence of CD among
T1DM children is 5–10 times higher than in the general
population [11] ranging from 3 to 16 %, as described by
Volta et al. [12].
In the present study, we aimed at further analyzing the
relationship between rotavirus infection and the patho-
genesis of CD using two different approaches: firstly, given
the high prevalence of CD in children with T1DM [13, 14],
we tested the sera of a group of children affected by
T1DM, with or without CD, for the presence of anti-VP7
peptide antibodies. The sera of some of T1DM patients
were available for the detection of antiviral antibodies,
before and after the onset of CD.
Secondly, we used a gene-array technique to analyze the
effects of purified anti-rotavirus VP7 peptide antibodies on
intestinal epithelial cells T84 that we have used in our
previous work [7] and that are commonly used to study the
intestinal barrier function.
The results obtained indicate that anti-VP7 antibodies
may have an important role in predicting the onset of CD
and that such antibodies modulate clusters of genes typi-
cally involved in the pathogenesis of celiac disease, further
confirming the link between rotavirus infection and CD.
Materials and methods
Patients
Three hundred and fifty-seven children affected by T1DM
have been evaluated prospectively. During the follow-up, 32
of them developed CD diagnosed on the basis of the presence
of anti-tTG and anti-endomysium (EMA) antibodies, detec-
ted by commercially available ELISA kits (EliA Celikey kit,
Phadia, Uppsala, Sweden and Antiendomysium, Eurospital
kit, Trieste, Italy, respectively) and by mucosal biopsy [15].
The presence of anti-VP7 antibodieswas assessed in 26 of the
32 T1DM-CD patients and was compared with a group of 37
T1DM children who did not develop CD.
Sera from8 of theT1DM-CDpatients (OnlineResource 1)
were available before and after the onset of CD andwere used
for the detection of anti-VP7 rotavirus peptide, anti-celiac
peptide, and anti-tTG (476-487) peptide IgA antibodies.
The time interval between the blood collection and the
CD onset ranged from 6 to 120 months.
To perform the gene-array analysis, anti-VP7 peptide anti-
bodies were isolated from sera of 20 patients with active dis-
ease, 12males and 8 females, aged 1–38 (mean = 16) years, at
diagnosis of biopsy confirmedCD, as previously described [7].
Briefly, the patients with CD included in the study
showed no evidence of other autoimmune diseases; all the
patients had serum anti-tTG and EMA IgA antibodies
before gluten-free diet (GFD). The duodenal histological
damage at diagnosis ranged from grade 3a to 3c, according
to Marsh’s classification [16].
Peptide synthesis
The rotavirus VP-7 peptide (VIQVGGSNVLDI), the celiac
peptide (VVKGGSSSLGW), the tTG peptide (RI-
RVGQSMNMGS), and the irrelevant control peptide
(VTLPKDSDVELP) were manually synthesized using the
standard method of solid-phase peptide synthesis, which
follows the 9-fluorenylmethoxycarbonyl (FMOC) strategy
with minor modifications [17].
All the synthesized compounds were purified by
reverse-phase high-performance liquid chromatography
(RP-HPLC) and the molecular weights were finally con-
firmed by electrospray mass spectrometry.
Fig. 1 Sequence homology between the celiac peptide and the
rotavirus VP7 protein and between the celiac peptide and tissue
transglutaminase. The peptide sequence was compared using the
BLASTP via the NCBI BLAST network service (: indicates identity
and asterisk indicates conservative substitutions)
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Cell culture
T84 cells were obtained from the American Type Culture
Collection (Manassas, VA, USA) and were grown with
media containing a 1:1 mixture of Ham’s F-12 nutrient
mixture and Dulbecco’s modified Eagle’s medium sup-
plemented with 6 % heat-inactivated fetal bovine serum,
15 mmol L-1N-2-hydroxyethylpiperazine-N’-2-ethanesul-
phonic acid (HEPES), 14.3 mmol L-1 NaHCO3, and
antibiotics (penicillin and streptomycin)–antimycotics (pH
7.4). Cells were passaged weekly on reaching confluence.
For experiments, cells were plated onto collagen-coated
permeable supports, where they were fed every 3 days and
used from days 7–14 (within fifth passage).
Cell monolayers were stimulated with antibodies affinity
purified against the VP7 rotavirus peptide or an irrelevant
control peptide (20 lg/ml) for 3 and 6 h. Cell pellets were
used for gene-array experiments, while soluble mediators
were measured in the cell supernatants.
Detection of antibodies anti-VP7, anti-celiac and anti-
transglutaminase peptides
The ELISA test for antibody binding to the synthetic
peptides has already been described elsewhere with minor
modifications [3].
Briefly, the synthetic peptides were used at a concen-
tration of 20 lg/ml in PBS to coat polystyrene plates
(Immulon 2HB, Thermo). Plates were then blocked for 1 h
with PBS 3 % BSA. Serum samples were diluted 1:100 in
diluting buffer (PBS 1 % BSA) and incubated overnight at
4 "C; plates were then washed twice with PBS/Tween and
twice with PBS.
The secondary reagent, alkaline phosphatase-conjugate
anti-human IgA antiserum (1:1,000 in diluting buffer;
Sigma), was incubated for 3 h at room temperature; plates
were then washed as described. The alkaline phosphatase
substrate (Sigma) was then added to the wells and the plates
read after 30 min or 1 h at a spectrophotometer set at 405 nm.
For the detection of anti-rotavirus VP7 peptide, anti-
celiac peptide, and anti-tTG peptide IgA antibodies, we
considered positive only the sera whose OD readings were
higher than 0.160, 0.105, and 0.110, respectively. OD
values higher than the mean plus three standard deviations
(SD) of each serum dilution of the control group were
considered positive.
Affinity purification of anti-peptide antibodies
Synthetic peptides (5 mg peptide per gram of dried
Sepharose powder) were coupled to Sepharose 4B (Phar-
macia, Uppsala, Sweden) according to the manufacturer’s
instructions. Serum Igs diluted in PBS were applied to the
columns. The columns were washed with PBS. Bound Igs
were eluted with 0.1 M glycine (pH 2.5) and dialyzed
against PBS. The purity of the preparations was assessed
by SDS-PAGE followed by silver staining; sometimes,
when albumin contamination was present in the purified
preparation, an additional step was added using an Albu-
min Removal Kit (Pierce). Antibody concentration
matching was performed using a densitometric analysis of
a silver stain of the purified material.
Preparation of cRNA and array analysis
Preparation of cRNA, hybridization, and scanning of probe
arrays were performed according to the protocols of the
manufacturer (Affymetrix, Santa Clara, CA, USA) by
IFOM-IEO Campus for Oncogenomics, Affymetrix
Microarray Unit (Milano, Italy) using the Human Genome
U133A 2.0 GeneChip (Affymetrix). This is a single array
representing 14,500 well-characterized human genes and
including more than 22,000 probe sets and 500, 000 dis-
tinct oligonucleotide features.
The different gene expression patterns were analyzed
using Array Assist version 5.0 (Stratagene, La Jolla, CA,
USA) which calculated background-adjusted, normalized,
and log-transformed intensity values applying the PLIER
algorithm [18]. The PLIER method uses quantile normali-
zation and runs an optimization procedure which deter-
mines the best set of weights on the perfect match and
mismatch for each probe pair. Finally, the normalized
background-corrected data were transformed to the log2
scale. A signal log2 ratio of 1.0 indicates an increase in the
transcript level by twofold change (2 F.C.) and -1.0
indicates a decrease by twofold (-2 F.C.). A signal log2
ratio of zero would indicate no change. We analyzed the
gene expression profiles in T84 cells incubated with anti-
VP7 peptide antibodies (test samples) or with anti-irrele-
vant peptide antibodies (control samples) at a concentration
of 20 lg/ml, for 3 and 6 h. Genes were selected for final
consideration when their expression was at least 1.5-fold
different in the test sample versus control sample at each
one time point.
Selected genes were submitted to a functional classifi-
cation according to the Gene Ontology (GO) annotations
(http://www.geneontology.org/).
Analysis of soluble mediators released
in the supernatant of T84 cells
Aliquots of the supernatant of the T84 cell cultures used to
perform the gene-array analysis, treated with affinity
purified anti-VP7 antibodies or with affinity purified anti-
control peptide antibodies, were filtered and kept frozen at
-80 "C until assayed.
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The presence of soluble mediators released in the super-
natants was analyzed by BIOCLARMA (Turin, Italy)
using Bio-Plex Human Cytokine Plex Panel (IL-1beta, IL-4,
IL-6, IL-8, IL-13, CCL11/eotaxin, FGF2, G-CSF/CSF3,
GM-CSF/CSF2, CXCL10/IP-10, and PDGF-B).
Statistical analysis
The Mann–Whitney U test was performed for comparison
of the anti-VP7 rotavirus peptide antibodies detection
between the T1DM and the T1DM-CD groups.
Student’s t-test for independent paired data was used to
compare the levels of molecules in the supernatant of cells
incubated with antiviral peptide antibodies or with anti-
bodies directed against an irrelevant peptide.
Results
Detection of anti-VP7 rotavirus, anti-celiac
and anti-transglutaminase peptides antibodies
Sera from 26 of the 32 T1DM-CD patients were tested in
ELISA assay for the presence of anti-VP7 rotavirus peptide
antibodies; results were compared with 37 T1DM patients.
Anti-VP7 rotavirus peptide antibodies were present in
21 out of 26 (81 %) T1DM-CD patients and in 10 out of 37
(27 %) T1DM patients. Figure 2 shows that the levels of
such antibodies, as detected by OD, are significantly dif-
ferent in the two populations (p\ 0.0001).
We tested 8 sera of T1DM-CD patients before and after
the CD onset for the presence of anti-VP7 rotavirus pep-
tide, anti-celiac peptide, and anti-tTG (aa 476–487) peptide
IgA antibodies. As shown in Table 1, six out of eight
patients (patients 1, 2, 4, 5, 7, and 8) were positive for anti-
VP7 rotavirus and anti-celiac peptides antibodies months
before the CD onset, when the usual serological screening
test was still negative. All these six patients maintained the
positivity to both peptides after the onset of the disease.
Of the remaining two cases, serum from patient 3
remained negative for the presence of anti-celiac and VP7
peptides antibodies in the two samples, whereas serum
from patient 6 became positive for the presence of the anti-
VP7 rotavirus peptide antibodies after the onset of CD.
Among the eight patients, only three (patients 1, 2, and 8)
showed a high response to the tTG peptide before the onset of
the disease and before the appearance of anti-tTG and EMA
positivity at the screening test; other three patients (patients 3,
4, and 5) showed a borderline response and two patients
(patients 6 and7) did not showany recognition of this peptide.
Finally, apart from patient 6, all the other 7 patients
resulted positive for the presence of anti-tTG peptide
antibodies after the onset of CD.
Gene-array analysis
We analyzed the gene expression profiles in T84 intestinal
cells treated with antibodies affinity purified against the
rotavirus VP7 peptide in order to identify clusters of
genes involved in the pathogenesis of intestinal damage in
CD.
Indeed, the treatment of T84 cells with purified anti-
rotavirus VP7 peptide antibodies had a profound impact on
the gene expression pattern: such antibodies up-regulated
(fold change C 1.5) 1,574 and 1,506 probe sets after 3 and
6 h of incubation, respectively. Moreover, 3,279 probe sets
after 3 h and 1,641 probe sets after 6 h were down-regu-
lated (fold change B-1.5). The complete list of the mod-
ulated genes (Online Resource 2) is deposited in the
‘‘ArrayExpress Archive database of functional genomics
experiments’’ at http://www.ebi.ac.uk/arrayexpress/.
The distribution of selected genes signal intensity after 3
and 6 h of treatment is shown by scatter plot graphs in
Fig. 3.
The Gene Ontology analysis of the corresponding regu-
lated transcripts showed that the vast majority of them are
Fig. 2 Levels of anti-VP7 rotavirus peptide IgA antibodies tested by
ELISA in sera of T1DM patients with or without CD. Square dots:
indicate the 8 patients with T1DM who developed CD analyzed
before and after the onset of CD. Here, the O.D. values obtained after
the CD onset are reported. Black line: threshold for positivity (O.D.
0.160). p value is calculated by Mann–Whitney U test
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involved in several biological processes that may play a role
in the pathogenesis of CD, including regulation of apopto-
sis, inflammatory and immune response, cell proliferation,
cell differentiation, cell junctions, matrix metalloproteases,
receptors and signal transducers, cytoskeleton components,
ion transport and exchange, metabolism, EGF pathway.
Table 2 shows an overview of selected genes within the
above-mentioned clusters.
Increased apoptosis is considered the main cause of
villous atrophy [19]. Several pro-apoptotic transcripts were
indeed up-regulated by the incubation of T84 cells with
anti-VP7 antibodies, including caspase recruitment domain
family, member 10, CARD10; suppressor of cytokine
signaling 3, SOCS3; TIMP metallopeptidase inhibitor 3,
TIMP3; caspase 10, apoptosis-related cysteine peptidase,
CASP10; amyloid beta precursor protein-binding, family
B, member 2, APBB2 and v-fos FBJ murine osteosarcoma
viral oncogene homolog, FOS.
Moreover, various anti-apoptotic genes were strongly
down-regulated such as the homeodomain interacting
protein kinase 3, HIPK3; optic atrophy 1, OPA1; spindlin
family, member 2, SPIN2, and Cas-Br-M ecotropic retro-
viral transforming sequence b, CBLB.
It has been proposed that an altered differentiation of
epithelial cells in the small intestine plays a role in the
generation of celiac lesions [19]. Several genes responsible
for differentiation mechanisms were down-regulated by the
treatment with anti-VP7 peptide antibodies including:
meprin A, beta (MEP1B), and v-myb myeloblastosis viral
oncogene homolog (MYB).
These molecules play an active role in the intestinal
epithelial development and crypt formation: at the early
stage, the expression of MEP1B in intestinal brush border
membranes directs epithelial differentiation and cell
migration and then MYB is required for fully functional
normal crypt formation, while in its absence, columnar/
enterocytes cells are reduced [20].
Table 1 Levels of anti-VP7, anti-celiac, and anti-transglutaminase peptide IgA antibodies tested by ELISA in sera of patients with celiac disease
before and after the disease onset
Patients Months before
the onset
Before the disease onset a After the disease onset
Celiac peptide VP7 peptide tTG peptide Celiac peptide VP7 peptide tTG peptide
Patient 1 6 0.123 0.517 0.191 0.126 0.511 0.225
Patient 2 28 0.226 0.350 0.173 0.234 0.360 0.284
Patient 3 14 0.097 0.103 0.101 0.102 0.128 0.140
Patient 4 120 0.104 0.244 0.101 0.129 0.212 0.149
Patient 5 72 0.111 0.340 0.109 0.205 0.460 0.160
Patient 6 16 0.070 0.016 0.031 0.058 0.179 0.025
Patient 7 60 0.114 0.215 0.084 0.228 0.326 0.119
Patient 8 16 0.278 0.267 0.258 0.276 0.235 0.192
a Before the disease onset: anti-tTG and EMA negativity at the screening test
Fig. 3 Comparative scatter plot of normalized relative signal inten-
sity (log10) between T84 cells treated with anti-VP7 peptide
antibodies versus T84 cells treated with anti-irrelevant peptide
antibodies. A: after 3 h, B: after 6 h of incubation. Green squares:
up-regulated genes; red squares: down-regulated genes
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Table 2 Gene expression in T84 cells after 3 and 6 h of stimulation with anti-VP7 rotavirus peptide antibodies
Probe set ID Accession number Gene title Gene symbol FC (3 h) FC (6 h)
Apoptosis
210025_s_at AY028896 Caspase recruitment domain family, member 10 CARD10 4.74 3.54
206359_at NM_003955 Suppressor of cytokine signaling 3 SOCS3 2.75 2.15
201148_s_at NM_000362 TIMP metallopeptidase inhibitor 3 TIMP3 2.12 1.64
211888_x_at AF111345 Caspase 10, apoptosis-related cysteine peptidase CASP10 2.57 NCa
216747_at U62325 Amyloid beta precursor protein-binding, family B, member 2 APBB2 3.09 1.60
209189_at BC004490 v-fos FBJ murine osteosarcoma viral oncogene homolog FOS 2.60 3.47
213697_at NM_005734 Homeodomain interacting protein kinase 3 HIPK3 -2.08 -1.98
216287_at AB011139 Optic atrophy 1 (autosomal dominant) OPA1 -8.05 -3.42
207841_at NM_019003 Spindlin family, member 2 SPIN2 -2.15 -1.92
208348_s_at U26710 Cas-Br-M ecotropic retroviral transforming sequence b CBLB -9.29 -8.63
Inflammatory and immune response
205082_s_at AB046692 Aldehyde oxidase 1 AOX1 2.11 2.51
204748_at NM_000963 Prostaglandin-endoperoxide synthase 2 PTGS2 1.76 2.26
202992_at NM_000587 Complement component 7 C7 3.11 3.04
205098_at NM_001295 Chemokine (C–C motif) receptor 1 CCR1 3.27 4.34
208304_at NM_001837 Chemokine (C–C motif) receptor 3 CCR3 2.80 3.47
206380_s_at NM_002621 Complement factor properdin CFP 2.92 1.76
208548_at NM_021002 Interferon, alpha 6 IFNA6 NCa 2.08
207932_at NM_002170 Interferon, alpha 8 IFNA8 2.23 1.53
206569_at NM_006850 Interleukin 24 IL24 2.19 1.65
217112_at NM_002608 Platelet-derived growth factor beta PDGFB 1.68 4.01
207442_at NM_000759 Colony stimulating factor 3 (granulocyte) CSF3 NCa 1.50
39402_at M15330 Interleukin 1, beta IL1B 1.80 1.50
207538_at NM_000589 Interleukin 4 IL4 2.00 1.72
205207_at NM_000600 Interleukin 6 (interferon, beta 2) IL6 NCa 1.51
202859_x_at NM_000584 Interleukin 8 IL8 1.86 1.62
204533_at NM_001565 Chemokine (C–X–C motif) ligand 10 CXCL10/IP10 NCa 1.82
210133_at D49372 Chemokine (C–C motif) ligand 11 CCL11 1.96 NCa
215078_at BT006967 Superoxide dismutase 2, mitochondrial SOD2 -2.06 NCa
209341_s_at AF080158 Inhibitor of kappa light polypeptide gene enhancer kinase beta IKBKB -2.25 -1.78
207433_at NM_000572 Interleukin 10 IL10 -3.56 -2.15
221470_s_at NM_014439 Interleukin 1 family, member 7 (zeta) IL1F7 -2.26 -1.67
Cell proliferation
210237_at AF120274 Artemin ARTN 1.96 2.10
213586_at U20498 Cyclin-dependent kinase inhibitor 2D CDKN2D 2.40 1.95
204463_s_at NM_001957 Endothelin receptor type A EDNRA 4.40 2.55
204422_s_at NM_002006 Fibroblast growth factor 2 (basic) FGF2 2.68 2.34
208449_s_at NM_006119 Fibroblast growth factor 8 FGF8 3.34 3.54
206742_at NM_004469 Vascular endothelial growth factor D FIGF 2.28 1.79
221722_x_at AF123652 Leucine zipper, putative tumor suppressor 1 LZTS1 4.14 6.12
Cell differentiation
215152_at NM_005375 v-myb myeloblastosis viral oncogene homolog MYB -1.99 -3.62
207251_at NM_005925 Meprin A, beta MEP1B -3.99 -4.31
Cell junctions
207025_at NM_020435 Gap junction protein, alpha 12, 47 kDa GJA12 1.88 1.85
207324_s_at NM_004948 Desmocollin 1 DSC1 -1.64 -2.22
221132_at NM_016369 Claudin 18 CLDN18 2.03 NCa
Diagnosis of Autoimmunity
123
Table 2 continued
Probe set ID Accession number Gene title Gene symbol FC (3 h) FC (6 h)
Metalloproteases
204943_at NM_021641 ADAM metallopeptidase domain 12 ADAM12 2.11 1.50
202828_s_at NM_004995 Matrix metallopeptidase 14 MMP14 2.29 2.26
222342_at NM_197941 ADAM metallopeptidase with thrombospondin type 1 motif, 6 ADAMTS6 5.06 6.96
204580_at NM_002426 Matrix metallopeptidase 12 (macrophage elastase) MMP12 NCa 1.56
206234_s_at NM_016155 Matrix metallopeptidase 17 (membrane-inserted) MMP17 1.58 1.50
Receptor and signal transducer
220821_at NM_001480 Galanin receptor 1 GALR1 5.22 3.37
207072_at NM_003853 Interleukin 18 receptor accessory protein IL18RAP 2.26 3.06
211533_at M22734 Platelet-derived growth factor receptor, alpha polypeptide PDGFRA 5.87 4.27
208256_at NM_001405 Ephrin-A2 EFNA2 1.87 2.17
205841_at NM_004972 Janus kinase 2 JAK2 2.20 2.64
211083_s_at NM_004721 Mitogen-activated protein kinase kinase kinase 13 MAP3K13 1.87 2.97
211437_at NM_006724 Mitogen-activated protein kinase kinase kinase 4 MAP3K4 2.79 2.80
204936_at NM_004579 Mitogen-activated protein kinase kinase kinase kinase 2 MAP4K2 2.07 3.14
206040_s_at NM_002751 Mitogen-activated protein kinase 11 MAPK11 4.01 2.08
216933_x_at S67788 Adenomatosis polyposis coli APC -2.06 -1.50
Cytoskeleton
205373_at NM_004389 Catenin (cadherin-associated protein), alpha 2 CTNNA2 2.25 3.43
216947_at NM_001927 Desmin DES 3.86 2.33
200600_at NM_002444 Moesin MSN -1.96 -2.58
209209_s_at NM_006832 Pleckstrin homology domain containing, family C, member 1 PLEKHC1 -2.44 -1.67
Ion transport
205410_s_at NM_001684 ATPase, Ca ?? transporting, plasma membrane 4 ATP2B4 2.41 2.15
212292_at NM_003045 Solute carrier family 7 SLC7A1 2.19 NCa
221106_at NM_016609 Solute carrier family 22 member 17 SLC22A17 3.26 3.30
208589_at NM_020389 Transient receptor potential cation channel, subfamily C, 7 TRPC7 1.50 2.64
220552_at NM_012471 Transient receptor potential cation channel, subfamily C, 5 TRPC5 2.73 2.63
208432_s_at NM_000721 Calcium channel, voltage-dependent, alpha 1E subunit CACNA1E NCa 2.12
211830_s_at AF211189 Calcium channel, voltage-dependent, alpha 1I subunit CACNA1I 2.60 1.50
208479_at NM_000217 Potassium voltage-gated channel, member 1 KCNA1 1.50 2.31
206765_at AF153820 Potassium inwardly rectifying channel, subfamily J, member 2 KCNJ2 2.20 2.70
207141_s_at NM_002239 Potassium inwardly rectifying channel, subfamily J, member 3 KCNJ3 6.19 3.78
214647_s_at NM_000410 Hemochromatosis HFE NCa 1.60
207212_at NM_004174 Solute carrier family 9 (sodium/hydrogen exchanger), member 3 SLC9A3/NHE3 -3.04 NCa
Metabolism
207262_at NM_001638 Apolipoprotein F APOF 4.69 4.14
216418_at AL133173 ATP-binding cassette, sub-family D (ALD), member 1 ABCD1 11.54 4.52
209601_at S69189 Acyl-coenzyme A oxidase 1, palmitoyl ACOX1 2.43 2.82
207015_s_at NM_003888 Aldehyde dehydrogenase 1 family, member A2 ALDH1A2 4.04 3.58
214315_x_at NM_004343 Calreticulin CALR 2.04 NCa
207316_at NM_001523 Hyaluronan synthase 1 HAS1 2.10 2.42
213723_s_at NM_000203 Iduronidase, alpha-L- IDUA 4.38 3.21
216529_at NM_005732 RAD50 homolog RAD50 6.45 3.44
214490_at NM_004042 Arylsulfatase F ARSF -3.20 -1.51
203178_at NM_001482 Glycine amidinotransferase GATM -5.70 -1.60
208019_at NM_003446 Zinc finger protein 157 (HZF22) ZNF157 -3.51 -9.46
202588_at NM_000476 Adenylate kinase 1 AK1 NCa -2.12
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In celiac crypt cell population, an increased division rate
has been observed, leading to crypt hyperplasia [19].
Consistently with this finding, in T84 cells, the anti-VP7
antibodies activate the transcription of several genes
involved in cell proliferation; up-regulated genes include
the following: artemin (ARTN), cyclin-dependent kinase
inhibitor 2D (CDKN2D), endothelin receptor type A
(EDNRA), fibroblast growth factor 2 (FGF2) and 8 (FGF8),
vascular endothelial growth factor D (FIGF), and leucine
zipper, putative tumor suppressor 1 (LZTS1).
Some of the genes up-regulated by the antibody treat-
ment are involved in the epidermal growth factor receptor
(EGFR) pathway including EGFR, v-akt murine thymoma
viral oncogene homolog 2 (AKT2), phosphoinositide-3-
kinase, catalytic, gamma polypeptide (PIK3CG), catenin
beta 1 (CTNNB1), ephrin-B2 (EFNB2), and ephrin-A2
(EFNA2).
Ephrin receptors and their ligands, ephrins, are involved
in developmental processes as they regulate cell migration
and cell adhesion; moreover, they influence the normal as
well as the pathological architecture of tissues, including
intestinal epithelium [21]. Interestingly, several genes
involved in the EGFR signaling pathway have been found
up-regulated in epithelial cells derived from active CD
patients, and EGFR expression is more pronounced in the
crypt regions of CD patients with active disease [22].
The EGFR signaling pathway members are thought to
regulate also cell proliferation and cytoskeleton reorgani-
zation. Interestingly, some genes associated with cyto-
skeleton organization are modulated in T84 cells exposed
to anti-VP7 antibodies including moesin (MSN), pleckstrin
homology domain containing, family C member 1 (PLE-
KHC1), desmin (DES), and catenin alpha 2 (CTNNA2).
MSN acts as cross-linker between plasma membranes and
actin-based cytoskeletons, PLEKHC1 defines a connection
between ECM adhesions and the actin cytoskeleton and
participates in the orchestration of actin assembly and cell
shape modulation, CTNNA2 is able to regulate microtu-
bule dynamics since it is directly involved in actin orga-
nization and therefore acts as a central player of
cytoskeleton rearrangements in response to extracellular
interactions.
As the epithelial layer architecture is damaged in active
celiac disease, the physiological functions of intestinal
cells are altered, and among these functions, cell adhesion
and transport are dysregulated [23].
The antibodies treatment also modulated several genes
involved in cell–cell adhesion, in particular tight junctions
proteins, as claudin 18 (CLDN18) and gap junctions pro-
teins as the gap junction protein alpha 12 (GJA12) were
up-regulated, while desmosomes protein desmocollin 1
was down-modulated. CLDN18 has been found to be up-
regulated during experimental colitis and in patients with
ulcerative colitis [24]. GJA12 is a gap junction protein and
it was postulated that an increased number of these junc-
tions may facilitate the diffusion of gluten peptides
between cells along the epithelial layer [23].
Desmocollin is a desmosomal protein required for cell to
cell adhesion and its down-regulation may contribute to
increased epithelial cell permeability, a key feature of
celiac disease.
Moreover, several genes coding for ion channels and
transporters such as ATPase, Ca ?? transport, plasma
membrane 4 (ATP2B4), solute carrier family 22 member
17 (SLC22A17), potassium voltage-gated channel, shaker-
related subfamily, member 1 (KCNA1), and potassium
Table 2 continued
Probe set ID Accession number Gene title Gene symbol FC (3 h) FC (6 h)
205939_at NM_000765 Cytochrome P450, family 3, subfamily A, polypeptide 7 CYP3A7 -2.12 -2.16
221561_at L21934 Sterol O-acyltransferase SOAT1 -1.98 -2.33
214970_s_at X17247 ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 ST6GAL1 -2.44 -1.83
206624_at NM_004654 Ubiquitin specific peptidase 9, Y-linked USP9Y -2.36 -3.28
205978_at NM_004795 Klotho KL 7.15 3.94
EGFR pathway
211607_x_at U48722 Epidermal growth factor receptor EGFR 2.11 NCa
211453_s_at M77198 v-akt murine thymoma viral oncogene homolog 2 AKT2 2.19 1.72
206370_at NM_002649 Phosphoinositide-3-kinase, catalytic, gamma polypeptide PIK3CG 2.89 2.52
202668_at NM_004093 Ephrin-B2 EFNB2 1.68 NCa
201533_at NM_001904 Catenin (cadherin-associated protein), beta 1, 88 kDa CTNNB1 1.71 1.65
205106_at NM_001018025 Mature T cell proliferation 1 MTCP1 1.52 NCa
201130_s_at NM_004360 Cadherin 1, type 1, E-cadherin (epithelial) CDH1 1.66 1.50
a Not significantly changed
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inwardly rectifying channel, subfamily J, member 3
(KCNJ3) were overexpressed in T84 cells treated with anti-
VP7 rotavirus antibodies. Noteworthy, an up-regulation of
genes coding for ion channels has been described in
intestinal epithelial cells [23], and ion transport is known to
be increased in celiac disease [25]. Indeed, intestinal epi-
thelial cells chronically exposed to IFN-gamma down-
regulate the Na(?)/H(?) exchangers NHE2 and NHE3
expression leading to inflammation-associated diarrhea
[26]. Moreover, increased levels of serotonin, which has
been implicated in the pathophysiology of diarrhea asso-
ciated with CD, are known to down-regulate NHE2 and
NHE3 expression [27]. Interestingly, NHE3 transcription is
down-regulated in T84 cells after treatment with anti-
rotavirus VP7 antibodies.
The gene encoding for the iron transporter hemochro-
matosis (HFE) was up-regulated in treated T84 cells. The
overexpression of this molecule has been associated with
the reduction in iron uptake typical of CD [28].
Several genes up-regulated in T84 cells treated with
anti-VP7 antibodies encode for matrix metallopoteases
(MMPs), including MMP-12. An increased expression of
several MMPs and in particular of MMP-12 has been
observed in biopsies of patients with active CD [19, 23].
The gene expression profiles of T84 cells show that the
anti-VP7 antibodies exert a proinflammatory effect since
they induced an overexpression of proinflammatory genes
such as prostaglandin-endoperoxide synthase 2, PTGS2;
chemokine (C–C motif) receptor 1, CCR1; chemokine
(C–C motif) receptor 3, CCR3; and the proinflammatory
interleukin 8, IL-8; they decreased the expression of anti-
inflammatory genes such as mitochondrial superoxide
dismutase 2, (SOD2) and the protective interleukin 10
(IL-10).
Another cluster of differentially expressed genes were
genes encoding for receptors and signal transducers mol-
ecules. Several of these genes such as galanin receptor 1
(GALR1), interleukin 18 receptor accessory protein
(IL18RAP), platelet-derived growth factor receptor, alpha
polypeptide (PDGFRA), and mitogen-activated protein
kinases (such as MAP3K13, MAP3K4, MAP4K2,
MAPK11) showed an increased expression in T84 cells
treated with anti-VP7 antibodies.
Galanin receptors are expressed by smooth muscle cells
lining the gastro-intestinal tract and mediate the effect of
galanin in altering intestinal motility. In particular, Gal1-R
is also expressed by the human T84 epithelial cell line and,
when stimulated, this receptor cause Cl- secretion. More-
over, Gal1-R expression is transcriptionally up-regulated
under inflammatory conditions and an increased receptor
expression was observed in the intestinal epithelium of
patients with inflammatory bowel disease and infectious
diarrhea. Therefore, this receptor plays an important role in
diarrhea associated with a variety of inflammatory disor-
ders [29].
Analysis of soluble mediators released
in the supernatant of T84 cells
The analysis of gene expression profiles was comple-
mented by the analysis of some of the corresponding sol-
uble mediators released by treated T84 cells.
Figure 4 shows the concentration (pg/ml) of the mole-
cules tested in the supernatants of T84 cells incubated with
antibodies against the irrelevant peptide and with anti-VP7
peptide antibodies.
A fulfilling correspondence was found for 9 transcripts
(CSF3, PDGFB, CXCL10, FGF2, IL1B, IL8, IL6, CCL11,
IL4) whose overexpression was paralleled by increased
secretion of the corresponding molecules in the supernatant
of T84 cells incubated with antiviral antibodies, after 3
and/or 6 h.
Other two molecules (IL13 and CSF2) did not show a
significantly difference in their concentration between
treated and control supernatants and the gene expression
levels was also similar in T84 cells treated with anti-VP7
peptide and anti-irrelevant peptide antibodies (1.19, 1.20
and 1.2, 1.3 F.C. respectively at 3 and 6 h of treatment;
data not shown).
Discussion
The aim of this study was to further analyze the link
between rotavirus infection and pathogenesis of CD. First
of all, we wanted to evaluate whether the presence of anti-
VP7 peptide antibodies precedes the onset of CD and
therefore whether the detection of such antibodies might be
used as a predictive marker for the onset of CD when anti-
tTG and anti-endomysium antibodies are still not detect-
able. To this aim, we tested the sera of patients with
T1DM, who present a high prevalence of CD.
Secondly, we wanted to study the effects of anti-viral
peptide antibodies on intestinal epithelial cells by means of
genes modulation complemented by the analysis of mole-
cules secreted in the supernatant, to confirm that such
antibodies are able to induce in vitro some of the features
observed in celiac epithelium in vivo.
A strong association between T1DM and CD has been
reported. Indeed, a CD prevalence as high as 7 % has been
observed in T1DM north Italian population [15].
Among our T1DM patients, nearly 9 % developed CD
(32 of 357), a percentage slightly higher than the one
already reported only a few years ago. These results
raise the question whether the prevalence of CD is
increasing among T1DM patients and whether this could
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be due to environmental factors such as food and viral
infections [13].
When we analyzed the levels of anti-rotavirus VP7
peptide antibodies in T1DM patients with CD compared to
T1DM patients without CD, we found statistically signifi-
cant higher level of antibodies in the first group, suggesting
that such antibodies are possibly related to the onset of CD.
Moreover, anti-VP7 peptide antibodies appeared before the
Fig. 4 Soluble mediators released in cell culture supernatants of T84
cells. T84 cells were treated with: anti-VP7 peptide antibodies (white
bar) and anti-irrelevant peptide antibodies (gray bar) at 3 and 6 h.
Results are expressed in pg/mL as mean of three independent
experiments. p value is calculated using the Student’s t-test for paired
independent samples
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onset of CD in 6 of the 8 T1DM patients analyzed, in
particular one patient had such antibodies 120 months
before evidence, both humoral and histological, of the
disease.
The VP7 rotavirus peptide shares a high degree of
sequence homology with the identified celiac peptide [7]
which is homologous also to the tTG 476–487 peptide.
Interestingly, before CD onset, all the six sera that recog-
nized the viral peptide recognized also the celiac peptide and
three of them recognized also the tTG peptide and another
one (patient 5) presented a borderline recognition. These
findings confirm our previous data on the ability of anti-
celiac peptide antibodies to cross-recognize the rotavirus-
derived peptide and, to a minor extent, the tTG peptide.
Altogether, the results of this first part of our work
further support a possible etiological link between rotavirus
infection and pathogenesis of CD.
Anti-rotavirus VP7 antibodies seem to be also directly
involved in the celiac disease pathogenesis as shown by the
gene-array results.
Indeed, the large majority of genes that are modulated
by the anti-VP7 antibodies in T84 cells have been reported
to play a role in the biological processes that lead to the
most important features of the disease.
Some of the modulated genes are involved in triggering
the apoptotic process and in the regulation of cell prolifera-
tion and differentiation. Therefore, the treatment of T84 cells
with the antiviral peptide antibodies induces the typical
alterations seen in CD since the gluten-induced small-
intestinal lesions are characterized by mucosal villous atro-
phy and crypt hyperplasia, associated with decreased dif-
ferentiation and increased proliferation of epithelial cells.
A gene-array analysis previously performed by Diosd-
ado et al. [30] suggested that, in the celiac villous crypt,
stem cells normally proliferate but fail to completely dif-
ferentiate with consequent formation of hyperplastic crypts
leading to villous atrophy.
Moreover, it has been shown that gliadin peptides
induce actin cytoskeleton rearrangements in a wide range
of cell types [31]. The gene expression profiles of the array
analysis reported in this work show a modulation of several
genes involved in cytoskeleton organization.
The gene-array results also reflect the dysregulation of
cell–cell adhesion molecules seen in CD, since genes
encoding for tight junctions and gap junctions proteins are
up-regulated, while desmosomes proteins are down-mod-
ulated by the treatment. These alterations are preceding
events of the decreased transepithelial resistance and of the
increased permeability that are typical features of the celiac
intestinal epithelium.
Moreover, the antibody treatment was also able to
modulate cellular ion transport in T84 cells. This
modulation includes the up-regulation of several ion
channels and transporter [23, 25] and the down-regulation
of the Na(?)/H(?) exchanger NHE3 that is present in
celiac intestinal epithelial cells. In particular, it has been
supposed that the reduction in NHE3 expression may play
a role in the onset of the celiac-associated diarrhea, one of
the major clinical features of the disease [27].
The gene-array data are also consistent with the
increased expression of several MMPs observed in the
biopsies of patients with active disease [19], and among
these, we want to point out the increased expression of
MMP-12 since it has been considered crucial for the
immunological mechanisms that lead to tissue injury [32].
Besides their classical role in connective tissue protein
turnover and degradation, MMPs may promote inflamma-
tion acting on chemokines and other inflammatory media-
tors [33].
Moreover, many genes involved in inflammation resul-
ted up-regulated by exposure of cells to the antibodies
indicating that such antibodies may induce a proinflam-
matory effect on T84 intestinal cells. This effect is
increased by the down-regulation of some anti-inflamma-
tory molecules such as IL-10.
Finally, the anti-VP7 antibodies up-regulated the
expression of several receptors such as Galanin receptor,
involved in inflammation-associated diarrhea, EGFR,
EGFR-pathway-associated molecules, involved in the
orchestration of epithelial cells proliferation, and signal
transducer molecules such as ephrin-A2 that acts as a key
regulator of developmental process in many epithelial
cells.
In conclusion, we describe here two important charac-
teristics of the previously identified anti-rotavirus VP7
antibodies that further support the link between rotavirus
infection and CD: first, the possibility that they may
identify subjects who will develop CD and second, the
ability of these antibodies to modulate sets of genes in
intestinal epithelial cells. Such genes are involved in
apoptosis, in alteration of the epithelial barrier integrity and
in inflammation, which are typical features of CD.
Early diagnosis of CD is necessary and is based on
periodical autoantibody screening following the diagnosis
of T1DM. In this regard, the evaluation of anti-VP7 rota-
virus antibodies may represent an additional and useful
marker with important predictive value.
It will be important to confirm the predictive value of
such antiviral antibodies in further studies including sub-
jects with a family history of CD and with genetic
predisposition.
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